Prevalence and Impact of Unacceptable Symptom State among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation's 2019 Annual Survey.

Disease activity Outcome measures Psoriasis Psoriatic arthritis QOL

Journal

JID innovations : skin science from molecules to population health
ISSN: 2667-0267
Titre abrégé: JID Innov
Pays: Netherlands
ID NLM: 101776173

Informations de publication

Date de publication:
Sep 2024
Historique:
received: 21 09 2023
revised: 26 04 2024
accepted: 01 05 2024
medline: 16 8 2024
pubmed: 16 8 2024
entrez: 16 8 2024
Statut: epublish

Résumé

The National Psoriasis Foundation surveyed a random, stratified sample of individuals with psoriatic disease in the United States to determine the prevalence of an unacceptable psoriatic arthritis (PsA) symptom state and its effect on depression and social participation. Acceptable and unacceptable levels of PsA were defined using established cutoff points (acceptable ≤4 vs unacceptable >4) on the Psoriatic Arthritis Impact of Disease 9. Psoriasis severity was defined by body surface area: mild < 3%, moderate-severe ≥ 3%. Depression was assessed utilizing the Patient Health Questionnaire 2. Social participation was assessed by the Patient Reported Outcome Information Measurement System Ability to Participate in Social Role and Activities-SF4a. The analysis cohort comprised 801 patients with PsA. Unacceptable disease activity level (Psoriatic Arthritis Impact of Disease >4) was reported by 59.6% of participants. After adjusting for age, sex, and psoriasis severity, individuals with likely depression (OR = 0.014,

Identifiants

pubmed: 39149524
doi: 10.1016/j.xjidi.2024.100292
pii: S2667-0267(24)00039-0
pmc: PMC11325781
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100292

Informations de copyright

© 2024 Published by Elsevier Inc. on behalf of the Society for Investigative Dermatology.

Auteurs

Melissa P Zundell (MP)

Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Alexis R Ogdie-Beatty (AR)

Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Lourdes Perez-Chada (L)

Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Hassan Hamade (H)

Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.

George C Gondo (GC)

National Psoriasis Foundation, Portland Oregon, USA.

Ali T Khan (AT)

Department of Occupational & Environmental Medicine, University of Washington, Seattle, Washington, USA.

Stacie J Bell (SJ)

National Psoriasis Foundation, Portland Oregon, USA.

Zachary Levy (Z)

Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Joseph F Merola (JF)

Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Alice B Gottlieb (AB)

Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Classifications MeSH